The Pelthos Therapeutics Inc. (PTHS) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret them. As a Nevada-incorporated biopharmaceutical company listed on the NYSE American, Pelthos files a range of documents with the U.S. Securities and Exchange Commission that describe its business, governance, and financial obligations.
Key filings include Form 8-K current reports, where Pelthos discloses material events such as financing transactions, product acquisitions, and governance changes. Recent 8-K filings describe a senior secured term loan facility with Horizon Technology Finance Corporation intended to support commercialization of ZELSUVMI and the launches of Xepi and Xeglyze, an asset purchase agreement for the Xeglyze head lice treatment, and a securities purchase agreement for senior secured convertible notes used to fund the acquisition and planned relaunch of Xepi and to accelerate ZELSUVMI commercialization.
Other 8-K items and the company’s definitive proxy statement on Schedule 14A provide detail on board composition, director compensation policies, annual meeting proposals, and shareholder voting results. These documents outline Pelthos’ governance structure, committee responsibilities, and the terms under which directors and executives are compensated and indemnified.
On Stock Titan, investors can review Pelthos’ periodic reports (such as Forms 10-K and 10-Q when filed) for information on revenue from ZELSUVMI, operating expenses, cash position, and risk factors related to its commercial dermatology portfolio and financing arrangements. Form 4 and related insider transaction reports, when available, show equity dealings by directors and officers, offering additional insight into insider alignment.
AI-driven summaries on this page highlight the most important points from lengthy filings, such as covenants in loan agreements, conversion terms in convertible notes, and implications of mergers and name changes. Real-time updates from EDGAR ensure that new Pelthos filings—whether related to financings, acquisitions, or governance—are quickly reflected, while the AI layer helps users understand how each document fits into the company’s broader strategy around ZELSUVMI, Xepi, and Xeglyze.
Pelthos Therapeutics Inc. director Peter Greenleaf reported selling a total of 797 shares of Common Stock in two open-market transactions on April 2, 2026. He sold 420 shares at a weighted average price of $20.5151 and 377 shares at $21.3614. According to the disclosure, these sales were made under a pre-arranged Rule 10b5-1 plan adopted on December 16, 2025, to help cover estimated tax obligations tied to vesting restricted stock units. After the transactions, Greenleaf directly holds 24,681 shares of Pelthos Therapeutics common stock.
Friedberg Ezra M reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics director Ezra M. Friedberg reported amended share awards tied to board compensation. The Form 4/A reclassifies prior filings so that restricted stock units (RSUs) granted under the 2023 Equity Incentive Plan now appear in the non-derivative table, each RSU delivering one share of common stock as it vests.
RSU awards cover 19,108 shares on July 2, 2025, 2,454 shares on November 13, 2024, and 6,450 shares on June 14, 2024, all at a stated price of $0.00 per share as compensation. These RSUs vest in equal quarterly installments over three years, subject to continued service. After the most recent award, Friedberg directly holds 82,585 common shares, with additional indirect holdings reported as 82,072 shares through Balmoral Financial Group LLC and 40,000 shares through Key Recovery Group LLC, which he may be deemed to beneficially own but disclaims except for his pecuniary interest.
Davis Todd C reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. director Todd C. Davis filed an amended insider report to reclassify prior equity awards as common stock grants rather than derivative holdings. The amendment covers restricted stock units (RSUs) granted under the company’s 2023 Equity Incentive Plan, each RSU settling into one share of common stock.
The filing reports grants of 19,108, 4,961 and 12,900 shares of common stock, all received as compensation for service on the board. These RSUs vest in equal quarterly installments over three years, conditioned on continued service. After these grants, Davis directly holds 39,886 common shares.
The amendment also notes an indirect holding of 1,500,000 shares recorded in the name of Ligand Pharmaceuticals Incorporated, where Davis serves as Chief Executive Officer and director. He may be deemed a beneficial owner of those shares but expressly disclaims beneficial ownership except to the extent of his pecuniary interest. All amounts have been adjusted for a 1-for-10 reverse stock split effective July 1, 2025.
Malamut Richard reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. director Richard Malamut filed an amended Form 4 to reclassify previously reported equity awards. The filing reports grants of 6,450, 19,108, and 2,454 shares of Common Stock at a price of $0.00 per share, reflecting restricted stock units (RSUs) issued under the company’s 2023 Equity Incentive Plan.
Each RSU represents the right to receive one share of Common Stock and vests in equal quarterly installments over three years, contingent on continued board service. The share amounts have been adjusted for the company’s 1-for-10 reverse stock split effective July 1, 2025. Following these awards, Malamut is shown with 28,012 directly held shares and an additional 1,040 shares indirectly held jointly with his spouse.
Plesha Scott M. reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. CEO and President Scott M. Plesha reported an equity compensation grant tied to restricted stock units. The Form 4 amendment shows an award of 83,678 shares of Common Stock, issuable upon settlement of RSUs granted under the company’s 2023 Equity Incentive Plan.
Each RSU represents one share of Common Stock and may be settled only in shares, subject to vesting. One-third of the RSUs vest on July 2, 2026, with the remaining balance vesting in equal quarterly installments over the following two years, contingent on continued service. Following this grant, Plesha holds 83,678 shares directly.
This filing amends a prior Form 4 by reclassifying the original RSU grant from the derivatives table to the non-derivative common stock table, clarifying how the award is reported rather than changing the underlying compensation terms.
Greenleaf Peter reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. director Peter Greenleaf reported an award of 25,478 shares of Common Stock, received as a grant of restricted stock units under the company’s 2023 Equity Incentive Plan. The award was granted as compensation for his service on the board of directors, at a stated price of $0.00 per share.
The RSUs vest over time: one-third of the underlying shares vested on July 2, 2025, with the remaining shares vesting in equal quarterly installments over the following two years, subject to continued service. Following this grant, Greenleaf directly holds 25,478 shares of Common Stock from this award.
Pauls Matthew reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. director Matthew Pauls reported an amended insider filing showing an equity award linked to 25,478 shares of common stock. These shares are issuable upon settlement of restricted stock units granted under the company’s 2023 Equity Incentive Plan as compensation for his board service.
The RSUs vest over time: one-third of the underlying shares vested on July 2, 2025, with the remaining units vesting in equal quarterly installments over two years, subject to his continued service. Following this grant, Pauls holds 25,478 shares of common stock directly.
Rangarao Sai reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. Chief Commercial Officer Rangarao Sai reported an amended insider filing reflecting an award of 30,518 shares of Common Stock, received as compensation in the form of restricted stock units (RSUs) under the company’s 2023 Equity Incentive Plan.
Each RSU represents the right to receive one share of Common Stock, settled solely in shares. One-third of the RSUs vests on July 2, 2026, with the remaining units vesting in equal quarterly installments over the following two years, contingent on Mr. Sai continuing in service. Following this grant, he directly holds 30,518 shares.
Baxter Richard B reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. director Richard B. Baxter reported an amended Form 4 reflecting a grant of 19,108 shares of Common Stock, issued at $0.00 per share upon settlement of previously granted restricted stock units (RSUs).
The RSUs were granted as compensation for his service on the board under the company’s 2023 Equity Incentive Plan. They vest in equal quarterly installments over three years, contingent on his continued service, and are settled solely in shares of Common Stock.
Francis Knuettel II reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. reported that its CFO, Treasurer and Secretary, Francis Knuettel II, received a grant of 33,472 restricted stock units (RSUs), each representing one share of common stock under the company’s 2023 Equity Incentive Plan. The RSUs were granted as compensation for his service as an officer and may be settled solely in shares of common stock, subject to vesting.
The RSUs vest with one-third of the shares on July 2, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, contingent on continued service. The filing also shows indirect holdings of common stock by Camden Capital LLC (10,000 shares) and the Lara Knuettel Revocable Trust (12,816 shares); Knuettel may be deemed to beneficially own these shares but disclaims beneficial ownership except for his pecuniary interest. Share amounts reflect a 1-for-10 reverse stock split effective July 1, 2025.